Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer

Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2021-03, Vol.124 (5), p.896-900
Hauptverfasser:	Liu, Shiqin, Shen, Michelle, Hsu, En-Chi, Zhang, Chiyuan Amy, Garcia-Marques, Fernando, Nolley, Rosalie, Koul, Kashyap, Rice, Meghan A., Aslan, Merve, Pitteri, Sharon J., Massie, Charlie, George, Anne, Brooks, James D., Gnanapragasam, Vincent J., Stoyanova, Tanya
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/2322 631/67/589/466 Biomarkers Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Brief Communication Cancer Research Cancer surgery Carrier Proteins - blood Cytokines - blood Drug Resistance EphA2 protein Epidemiology Follow-Up Studies Humans Immunohistochemistry Male Metastases Metastasis Molecular Medicine Oncology Pleiotrophin Prognosis Prostate cancer Prostatectomy Prostatectomy - mortality Prostatic Neoplasms - blood Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Proteomics Survival Rate Urological surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!